Featured Press Releases

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Merz Aesthetics launches Ultherapy PRIME, the next generation of nonsurgical skin lifting treatments

Merz Aesthetics launches Ultherapy PRIME, the next generation of nonsurgical skin lifting treatments

  • 23 Sep 2024

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced the launch...

CollPlant Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CollPlant Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Leqembi Secures Approval for Alzheimer

Leqembi Secures Approval for Alzheimer's Disease Treatment in Hong Kong

T3D Therapeutics to present Phase 2 results of T3D-959 for reducing Alzheimer

T3D Therapeutics to present Phase 2 results of T3D-959 for reducing Alzheimer's amyloid plaques

Novo Nordisk’s Ozempic pill—the only FDA-approved oral peptide GLP-1 for adults with Type 2 Diabetes—will soon be available in the U.S

Novo Nordisk’s Ozempic pill—the only FDA-approved oral peptide GLP-1 for adults with Type 2 Diabetes—will soon be available in the U.S

Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

  • Bayer
  • 15 Jun 2026
EVERY and Huvepharma Announce Fourfold Expansion of Production Capacity

EVERY and Huvepharma Announce Fourfold Expansion of Production Capacity

  • The EVERY Company
  • 15 Jun 2026
Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

  • Incyte
  • 15 Jun 2026
AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

  • AbbVie
  • 12 Jun 2026
Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

  • QUIRIS Healthcare
  • 11 Jun 2026
Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

  • NurtureBio
  • 11 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.